Navigating the Complexities of NTM Lung Disease
From Timely Diagnosis to Evidence-Based Therapeutic Strategies

Program Medium 
Internet-based program

Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period September 7, 2026 through September 7, 2028, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view activity, totaling 1.0 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity
1.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview
In this web-based program, physicians will learn how recent developments in basic and clinical research have helped to advance the understanding and management of non-tubercular mycobacterial (NTM) lung disease

Release Date
September 7, 2026

Expiration Date
September 7, 2028

Intended Audience
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with non-tubercular mycobacterial (NTM) pulmonary infection, including infectious disease specialists, pulmonary medicine specialists, and related clinicians.

Registration
Participation in this activity is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support
This activity is supported by an independent medical education grant from Insmed.

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the UMASS Chan Medical School and CMEducation Resources, LLC. The UMASS Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
The UMASS Chan Medical School, Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure
It is the policy of the UMASS Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the UMASS Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Prof. Francesco Blasi, MD, FERS – Program Chair
Professor of Respiratory Medicine
Department of Pathophysiology and Transplantation, 
Università degli Studi di Milano
Vice Rector for Relations with the National Health Service
Università degli Studi di Milano
Dean of the School of Medicine, Università degli Studi di Milano
Milan, Itraly

Grants, speaking and conference invitations from  AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Grifols, Insmed, Menarini, MSD, OM Pharma, Pfizer, Sanofi, UCB, Vertex, and Zambon

Stefano Aliberti, MD
Full Professor in Respiratory Medicine
Humanitas University, Milan, Italy 
Chief, Pulmonary Department
IRCCS Humanitas Research Hospital, Milan, Italy
Chair, Italian Registry of Pulmonary Non-Tuberculous
Mycobacteria (IRENE)

Consulting: Bayer Healthcare, Grifols, AstraZeneca, Zambon, Chiesi, Insmed, GlaxoSmithKline, Menarini, ZetaCube Srl
Grants: Insmed, Fisher & Paykel

Professor Michael Loebinger MA FRCP PhD
Director of the Lung Division, Clinical Director of Laboratory Medicine, Deputy Medical Director, Consultant Respiratory Medicine,
Royal Brompton & Harefield Hospitals
Royal Brompton Hospital, Sydney Street, London, SW3 6NP
Guys and St Thomas’ NHS Foundation Trust
Professor of Practice (Respiratory Medicine),
National Heart and Lung Institute
Imperial College London

Received consultancy and/or lecture fees from Insmed, Grifols, AstraZeneca, Armata, and Chiesi over past 3 years

Program Managers and Web Editor Disclosure 
Program Managers Gideon Bosker, MD and Denise Leary have nothing to disclose.

Educational Objectives
Upon completion of this activity, participants will be able to:

  • Apply the results of recent clinical trials (ARISE) focused on Quality-of-Life (Bronchiectasis), time to culture positivity (TTP), and predicting rapidity of culture conversion based on antimicrobial treatment options
  • Assess persons with NTM pulmonary disease, with improved skills at applying radiographic predictive criteria, patient-reported outcomes (PRO), TTP, and other clinical features that would suggest the need for more intensive, inhalation-based antimicrobial treatment
  • Assess the severity of MAC pulmonary disease in order to better predict which persons with this condition will likely accelerate microbial conversion, improve bronchiectatic and respiratory symptoms, and report improved functional status based on antimicrobial treatment decisions
  • Understand, interpret, and apply the new Year 2020 Updated ATS/IDSA/ERS Guidelines for NTM-LD; and how to apply new antimicrobial guidelines and recommendations contained in the new ATS/IDSA/ERS clinical practice statements
  • Compare and differentiate the mechanism of action and delivery systems of different antimicrobial formulations and how these MOA will affect microbial conversion and eradication in MAC lung disease
  • Recognize patients and symptoms that suggest the need to evaluate and assess—microbiologically and radiographically—persons with COPD, bronchiectasis, history of TB and other co-morbid conditions that place them at high risk for acquiring NTM-LD
  • Implement clinical strategies and adjunctive measures that improve regimen adherence for inhaled antimicrobial formulations approved for treatment of NTM-LD; and, that ensure, once started, antimicrobial treatment plans can be adhered to and a full, planned course of antimicrobial therapy can be completed until evidence of microbial conversion is documented
  • Discuss the epidemiology and disease burden for NTM-LD based on prevalence, susc


Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Disclaimer

Copyright © 2026 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.5